FindTrial
Sign In

Using GATA-3 and KRT 5/6 IHC markers for molecular phenotyping of bladder carcinoma.

Using GATA-3 and KRT 5/6 IHC markers for molecular phenotyping of bladder carcinoma: A Cross sectional study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/063238
Enrollment
61
Registered
2024-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C679- Malignant neoplasm of bladder, unspecified

Interventions

Control Intervention1: Nil: Nil

Sponsors

ROHILKHAND MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All histopathologically confirmed cases of bladder carcinoma that will be received in our department.

Exclusion criteria

Exclusion criteria: The biopsy reported as unsatisfactory and patients who are not willing to give consent. Tissue is insufficient for reporting.

Design outcomes

Primary

MeasureTime frame
To determine the immunohistochemical expression of GATA-3 and KRT 5/6 in all histologically confirmed cases of urinary bladder carcinoma and categorise them in basal and luminal phenotypes accordingly.Timepoint: 7 days—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactMehnaz Munawar

Rohilkhand medical college and hospital

drnitesh@gmail.com9997872559

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026